LON:PRM

Proteome Sciences Final Earnings Results & Report

Proteome Sciences logo
GBX 1.04 -0.13 (-11.11%)
As of 11/20/2026 12:40 PM Eastern

Proteome Sciences reported Final earnings on April 15, 2026. The company reported EPS of -GBX 1.04, while revenue was £3.76 million.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

Proteome Sciences EPS Results

Actual EPS
-GBX 1.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Proteome Sciences Revenue Results

Actual Revenue
£3.76 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Proteome Sciences Final Earnings FAQ

Proteome Sciences (LON:PRM) reported earnings of -GBX 1.04 per share for Final. The report was announced on Wednesday, April 15, 2026.

Proteome Sciences reported revenue of £3.76 million for Final.

Proteome Sciences Earnings Headlines

PRM.L - | Stock Price & Latest News | Reuters
Are Tesla and SpaceX Going Bankrupt?
Tesla and SpaceX shares crashed right after Democrats took the House and the Senate in the midterm election. Elon Musk backed President Trump and donated millions to Republicans, and many believe he will become a political target. Brownstone Research founder Jeff Brown has seen Musk's new technology on camera. He says he is more convinced than ever that nothing can stop the coming Elon Musk revolution.tc pixel
Proteome Sciences H1 Loss Narrows
See More Proteome Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Proteome Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Proteome Sciences and other key companies, straight to your email.

About Proteome Sciences

Proteome Sciences (LON:PRM) provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

View Proteome Sciences Profile